BIOCEUTICALS Arzneimittel

Bioceuticals Arzneimittel GmbH is a German biotechnology and pharmaceutical company that operates as a specialized subsidiary of STADA Arzneimittel AG. The company is primarily recognized for its expertise in the development and production of biosimilars, most notably Silapo (epoetin zeta). Silapo was one of the first biosimilar erythropoietins to receive approval from the European Medicines Agency (EMA) for the treatment of anemia associated with chronic renal failure and chemotherapy. Bioceuticals serves as a center of excellence for biologic development within the STADA Group, focusing on providing cost-effective alternatives to high-cost reference biologics. The company's products are distributed through STADA's global network and various international licensing agreements.